A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients
Clinical and Translational Medicine · 2024
DOI: 10.1002/ctm2.1627 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Medicine, 2024. Verfasst von Michael B Lilly und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NCI NIH HHS, NCATS NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Our preclinical studies showed that lycopene enhanced the anti‐prostate cancer efficacy of docetaxel in animal models. A phase I trial (NCT0149519) was conducted to identify an optimum dose of synthetic lycopene in combination with docetaxel (and androgen blockade [androgen deprivation therapy, ADT]), and to evaluate its effect on the safety and pharmacokinetics of docetaxel in men with metastatic prostate cancer.
Methods
Subjects were treated with 21‐day cycles of 75 mg/m 2 docetaxel (and ADT), plus lycopene at 30, 90 or 150 mg/day. A Bayesian model averaging continual reassessment method was used to guide dose escalation. Pharmacokinetics of docetaxel and multiple correlative studies were carried out.
Results
Twenty‐four participants were enrolled, 18 in a dose escalation cohort to define the maximum tolerated dose (MTD), and six in a pharmacokinetic cohort. Docetaxel/ADT plus 150 mg/day synthetic lycopene resulted in dose‐limiting toxicity (pulmonary embolus) in one out of 12 participants with an estimated probability of .106 and thus was chosen as the MTD. Lycopene increased the AUC inf and C max of plasma docetaxel by 9.5% and 15.1%, respectively. Correlative studies showed dose‐related changes in circulating endothelial cells and vascular endothelial growth factor A, and reduction in insulin‐like growth factor 1R phosphorylation, associated with lycopene therapy.
Conclusions
The combination of docetaxel/ADT and synthetic lycopene has low toxicity and favourable pharmacokinetics. The effects of lycopene on biomarkers provide additional support for the toxicity‐dependent MTD definition. Highlights The maximum tolerated dose was identified as 150 mg/day of lycopene in combination with docetaxel/ADT for the treatment of metastatic prostate cancer patients. Small increases in plasma exposure to docetaxel were observed with lycopene co‐administration. Mechanistically significant effects were seen on angiogenesis and insulin‐like growth factor 1 signalling by lycopene co‐administration with docetaxel/ADT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA.
- Department of Urology, University of California, Irvine, California, USA.
- Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA.
- Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
- Department of Biostatistics, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Xiaolin Zi
Förderung
- BLRD VA
- NCI NIH HHS
- NCATS NIH HHS
- National Cancer Institute
- Chao Family Comprehensive Cancer Center
Zitieren
APA
Lilly, M. B., Wu, C., Ke, Y., Chen, W. P., Soloff, A. C., Armeson, K., Yokoyama, N. N., Li, X., Song, L., Yuan, Y., McLaren, C. E., & Zi, X. (2024). A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1627
Vancouver
Lilly MB, Wu C, Ke Y, Chen WP, Soloff AC, Armeson K, et al. A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients. Clinical and Translational Medicine. 2024. doi:10.1002/ctm2.1627
BibTeX
@article{Lilly2024,
author = {Lilly, Michael B and Wu, Chunli and Ke, Yu and Chen, Wen-Pin and Soloff, Adam C and Armeson, Kent and Yokoyama, Noriko N and Li, Xiaotian and Song, Liankun and Yuan, Ying and McLaren, Christine E and Zi, Xiaolin},
title = {A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients},
journal = {Clinical and Translational Medicine},
year = {2024},
doi = {10.1002/ctm2.1627}
}
EUVIMED